​

TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TMDX Stock Forecast

TransMedics Group (TMDX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $110.60, with a high of $125.00 and a low of $90.00. This represents a 29.54% increase from the last price of $85.38.

$50 $80 $110 $140 $170 $200 High: $125 Avg: $110.6 Low: $90 Last Closed Price: $85.38

TMDX Stock Rating

TransMedics Group stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

TMDX Price Target Upside V Benchmarks

TypeNameUpside
StockTransMedics Group29.54%
SectorHealthcare Stocks 33.91%
IndustryMedical Device Stocks20.97%

Price Target Trends

1M3M12M
# Anlaysts--14
Avg Price Target--$151.86
Last Closing Price$85.38$85.38$85.38
Upside/Downside--77.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25153--9
Mar, 25153--9
Feb, 25153--9
Jan, 25153--9
Dec, 24353--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2024David RescottRobert W. Baird$120.00$67.3678.15%40.55%
Dec 11, 2024Matt O'BrienPiper Sandler$90.00$67.3633.61%5.41%
Oct 29, 2024Joe VruwinkRobert W. Baird$150.00$88.7069.11%75.69%
Oct 29, 2024Jason MillsCanaccord Genuity$109.00$126.24-13.66%27.66%
Oct 29, 2024Mike MatsonNeedham$109.00$126.24-13.66%27.66%
Oct 29, 2024Suraj KaliaOppenheimer$125.00$126.24-0.98%46.40%
Sep 23, 2024David RescottRobert W. Baird$200.00$159.5025.39%134.25%
Sep 04, 2024Matt O'BrienPiper Sandler$180.00$158.4213.62%110.82%
Aug 21, 2024Mike MatsonNeedham$208.00$166.1825.17%143.62%
Aug 01, 2024William PlovanicCanaccord Genuity$169.00$164.023.04%97.94%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024Piper SandlerOverweightOverweighthold
Oct 29, 2024William BlairOutperformOutperformhold
Oct 29, 2024StephensBuyBuyhold
Oct 29, 2024Canaccord GenuityBuyBuyhold
Oct 29, 2024NeedhamBuyBuyhold
Oct 29, 2024OppenheimerOutperformOutperformhold
Oct 24, 2024Piper SandlerOverweightOverweighthold
Sep 24, 2024StephensBuyBuyhold
Sep 05, 2024Cowen & Co.BuyBuyhold
Sep 04, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.16$-1.60$-1.23$-0.77$1.07----
Avg Forecast$-1.19$-1.58$-1.33$-0.93$0.98$1.47$2.38$2.91$3.71
High Forecast$-1.11$-1.46$-1.30$-0.90$1.05$1.70$2.72$2.95$3.76
Low Forecast$-1.28$-1.69$-1.34$-0.96$0.91$1.17$1.72$2.84$3.62
Surprise %-2.52%1.27%-7.52%-17.20%9.18%----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$25.64M$30.26M$93.46M$241.62M$441.54M----
Avg Forecast$23.98M$28.29M$86.22M$228.47M$429.57M$524.07M$635.61M$787.30M$923.65M
High Forecast$25.32M$29.87M$87.01M$230.40M$430.57M$529.01M$636.81M$798.35M$933.95M
Low Forecast$22.67M$26.74M$84.84M$226.23M$428.45M$517.83M$634.40M$776.25M$906.76M
Surprise %6.92%6.98%8.39%5.76%2.79%----

Net Income Forecast

$-50M $-10M $30M $70M $110M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.75M$-44.22M$-36.23M$-25.03M$35.46M----
Avg Forecast$-38.78M$-33.47M$-36.82M$-35.78M$32.64M$48.33M$84.88M$92.50M$120.48M
High Forecast$-36.02M$-26.78M$-29.46M$-28.62M$34.10M$55.13M$88.42M$96.00M$122.22M
Low Forecast$-41.60M$-40.17M$-44.18M$-42.93M$29.64M$38.09M$56.06M$92.38M$117.61M
Surprise %-25.86%32.09%-1.60%-30.05%8.66%----

TMDX Forecast FAQ

Is TransMedics Group stock a buy?

TransMedics Group stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that TransMedics Group is a favorable investment for most analysts.

What is TransMedics Group's price target?

TransMedics Group's price target, set by 9 Wall Street analysts, averages $110.6 over the next 12 months. The price target range spans from $90 at the low end to $125 at the high end, suggesting a potential 29.54% change from the previous closing price of $85.38.

How does TransMedics Group stock forecast compare to its benchmarks?

TransMedics Group's stock forecast shows a 29.54% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the medical device stocks industry (20.97%).

What is the breakdown of analyst ratings for TransMedics Group over the past three months?

  • April 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is TransMedics Group’s EPS forecast?

TransMedics Group's average annual EPS forecast for its fiscal year ending in December 2025 is $1.47, marking a 37.38% increase from the reported $1.07 in 2024. Estimates for the following years are $2.38 in 2026, $2.91 in 2027, and $3.71 in 2028.

What is TransMedics Group’s revenue forecast?

TransMedics Group's average annual revenue forecast for its fiscal year ending in December 2025 is $524.07M, reflecting a 18.69% increase from the reported $441.54M in 2024. The forecast for 2026 is $635.61M, followed by $787.3M for 2027, and $923.65M for 2028.

What is TransMedics Group’s net income forecast?

TransMedics Group's net income forecast for the fiscal year ending in December 2025 stands at $48.33M, representing an 36.27% increase from the reported $35.46M in 2024. Projections indicate $84.88M in 2026, $92.5M in 2027, and $120.48M in 2028.